Infarction, Myocardial Clinical Trial
— FreeO2 SCAOfficial title:
Comparaison of 2 SpO2 Level Measured by Pulse Oxymetry in Complications of Acute Coronary Syndrome.
Verified date | December 2017 |
Source | Laval University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
During acute coronary syndrome, the American College of Cardiology and the American Heart
Association recommend oxygen delivery to patients with less than 90% oxygen saturation.
Oxygen therapy in these patients for a duration of at least 6 hours, but also stipulates that
it is reasonable to administer oxygen to all acute coronary syndrome patients during the
first six hours following the presentation. Hyperoxia also has well-established risks.
Our research hypotheses are:
(I) that current practices tend to use high oxygen flows resulting in high SpO2 levels during
acute coronary syndrome.
(II) there is a high rate of desaturation in patients with acute coronary syndrome and an
automatic adaptation of oxygen flows may reduce this frequency.
(III) that excessive oxygenation targets have no advantage. Our hypothesis is that
maintaining a SpO2 of 90 to 94% is at least equivalent when compared to higher saturation
objectives (SpO2 of 94 to 100%) with regard to the occurrence of complications in the patient
in acute coronary syndrome . We will use two SpO2 targets with the FreeO2 system, 92 and 97%.
Status | Completed |
Enrollment | 60 |
Est. completion date | April 13, 2017 |
Est. primary completion date | August 8, 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients should have a proven diagnosis of acute high risk coronary syndrome as defined by the American Heart Association: - myocardial infarction with or without ST segment elevation: Ischemic changes in the electrocardiogram and positive cardiac biomarkers. - or Unstable angina: Typical or atypical cardiac symptoms, Ischemic electrocardiographic changes, Normal cardiac biomarkers. Exclusion Criteria: - inclusion in another study refusing co-enrollment - chronic obstructive pulmonary disease with CO2 retention - sleep apnea-hypopnea syndrome with CPAP - traumatic brain injury - pregnancy - Age <18 years - Mechanical invasive or non-invasive ventilation - patient needing more than 5 lpm of oxygen to have SpO2 > 95% |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Laval University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The frequency of significant desaturations (SpO2 <90% for at least 30 seconds) | 24 hours | ||
Secondary | Significant rhythm disorders, ischemic events | 24 hours | ||
Secondary | The percentage of time spent in the target SpO2 area in the second and third groups, defined as SpO2 +/- 2% of the targeted SpO2 (range 90-94% for group 92% and range 95-99% for group 97%) | 24 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00426751 -
Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI)
|
Phase 3 | |
Completed |
NCT00196274 -
Autonomic Regulation Trial (ART)
|
N/A | |
Recruiting |
NCT04000412 -
A Novel Myocardial Impedance Mapping System for Ablation of Post-infarction Ventricular Arrhytmias in Humans
|
||
Completed |
NCT00196261 -
Innovative Stratification of Arrhythmic Risk (ISAR-Trial): Long-Term Prediction
|
N/A | |
Completed |
NCT04096079 -
Post-ROSC Electrocardiogram After Cardiac arrEst
|
||
Completed |
NCT05123885 -
Wearable Then Implantable Cardiac Defibrillator After Myocardial Infarction
|